A phase III study for patients relapsing or progressing after autologous transplantation on total therapy 2 (TT2, UARK 98-026): Bortezomib [Velcade], thalidomide and dexamethasone versus bortezomib, melphalan, and dexamethasone [VMD].

Trial Profile

A phase III study for patients relapsing or progressing after autologous transplantation on total therapy 2 (TT2, UARK 98-026): Bortezomib [Velcade], thalidomide and dexamethasone versus bortezomib, melphalan, and dexamethasone [VMD].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2011

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TT2
  • Most Recent Events

    • 11 Aug 2011 Actual initiation date changed from Jul 2007 to Aug 2006 as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Primary endpoint changed (participant survival) as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top